These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 8375642)

  • 1. [Follow-up of tumor markers in evaluating the effectiveness of chemo- or hormone therapy of metastatic breast cancer].
    Kürzl R; Kuss E
    Geburtshilfe Frauenheilkd; 1993 Aug; 53(8):585-9. PubMed ID: 8375642
    [No Abstract]   [Full Text] [Related]  

  • 2. [Follow-up of tumor markers in evaluating the effectiveness of chemo- or hormone therapy in metastatic breast cancer].
    Möbus V; Paula J; Beck T; Crombach G; Kreienberg R
    Geburtshilfe Frauenheilkd; 1993 Jan; 53(1):24-9. PubMed ID: 8440454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The early detection of disseminated (metastasized) breast cancer by serial tumour marker measurements.
    Jäger W
    Eur J Cancer Prev; 1993 Nov; 2 Suppl 3():133-9. PubMed ID: 8298443
    [No Abstract]   [Full Text] [Related]  

  • 4. [Is follow-up of breast cancer with CEA and CA 15-3 justified?].
    Fritsche E; Benz J
    Helv Chir Acta; 1992 May; 59(1):225-9. PubMed ID: 1526832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Tumor markers in metastatic breast carcinoma: correlations with clinical response].
    Winer Y; Martini MC; Pastorino G; Moraglio L; Vallauri M; Brondi P; Brema F
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):127-30. PubMed ID: 2092107
    [No Abstract]   [Full Text] [Related]  

  • 6. Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma.
    al-Jarallah MA; Behbehani AE; el-Nass SA; Temim L; Ebraheem AK; Ali MA; Szymendera JJ
    Eur J Surg Oncol; 1993 Feb; 19(1):74-9. PubMed ID: 8436243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum CEA, CA 15-3, and MCA in breast cancer patients: a clinical evaluation.
    Repetto L; Onetto M; Gardin G; Costanzi B; Giudici S; Vitiello E; Merlini L; Naso C; Zannini C; Paganuzzi M
    Cancer Detect Prev; 1993; 17(3):411-5. PubMed ID: 8402728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Tumor markers in the diagnosis and prognosis of breast cancer].
    Seliuzhitskiĭ IV; Skvortsov SV; Lytsar BN; Khomenko LP
    Klin Med (Mosk); 1993; 71(2):25-7. PubMed ID: 8046917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [CA 15-3 associated with CEA and TPA in the follow-up of breast carcinoma].
    Maffei S; Rudoni M; Antonini G; Sacchetti G; Krengli M
    Minerva Med; 1990 Nov; 81(11):759-63. PubMed ID: 2255409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The clinico-diagnostic significance of tumor markers in malignant neoplasms].
    Seliuzhitskiĭ IV; Skvortsov SV; Lytsar' BN
    Voen Med Zh; 1993 Mar; (3):27-8. PubMed ID: 8498043
    [No Abstract]   [Full Text] [Related]  

  • 11. Circadian rhythms of tumor markers in breast cancer patients.
    Touitou Y; Bailleul F; Lévi F; Bogdan A; Touitou C; Metzger G; Mechkouri M
    Prog Clin Biol Res; 1990; 341A():59-66. PubMed ID: 2217278
    [No Abstract]   [Full Text] [Related]  

  • 12. Breast cancer and tumor markers.
    Castellaro E; Francioni S; Pastore M
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):43-7. PubMed ID: 2092148
    [No Abstract]   [Full Text] [Related]  

  • 13. [Comparison of the estrogen and progesterone receptor content of primary breast cancers without skeletal or visceral metastasis with tumor marker MCA, CEA and CA 15-3 serum concentration at the time of surgery].
    Seifert M; Wierrani F; Kubista E; Spona J
    Gynakol Rundsch; 1991; 31 Suppl 2():397-8. PubMed ID: 1790992
    [No Abstract]   [Full Text] [Related]  

  • 14. Kinetic use of tumor markers in the follow-up of patients operated for primary breast cancer.
    Gion M; Fila G; Biasioli R; Vignati G; Mione R; Saracchini S; Rinaldi E; Testa E; Bruscagnin G
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):1-7. PubMed ID: 2092100
    [No Abstract]   [Full Text] [Related]  

  • 15. Predictive value of CEA and CA 15-3 in the follow up of invasive breast cancer.
    Sütterlin M; Bussen S; Trott S; Caffier H
    Anticancer Res; 1999; 19(4A):2567-70. PubMed ID: 10470196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A checklist for suitability of biomarkers as surrogate endpoints in chemoprevention of breast cancer.
    Bogoch S; Bogoch ES
    J Cell Biochem Suppl; 1994; 19():173-85. PubMed ID: 7823589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A patient with pulmonary metastasis from breast cancer after surgery who responded to S-1].
    Yoneyama K; Yamada A; Koshida Y; Toriumi F; Murayama T; Toeda H; Imazu Y; Motegi K; Akamatsu H; Ooyama R
    Gan To Kagaku Ryoho; 2007 Jul; 34(7):1143-6. PubMed ID: 17637559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [CA 15-3 and CEA as tumor markers in the diagnosis of the recurrence of breast cancer].
    Engel K; Schmid H; Hanke J; Kaufmann M; Müller A
    Geburtshilfe Frauenheilkd; 1988 May; 48(5):309-12. PubMed ID: 3165077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients.
    Lauro S; Trasatti L; Bordin F; Lanzetta G; Bria E; Gelibter A; Reale MG; Vecchione A
    Anticancer Res; 1999; 19(4C):3511-5. PubMed ID: 10629644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Tumor markers in breast cancer].
    Kurebayashi J
    Gan To Kagaku Ryoho; 2004 Nov; 31(12):2077-81. PubMed ID: 15570944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.